CTNM
Income statement / Annual
Last year (2023), Contineum Therapeutics, Inc. Class A Common Stock's total revenue was $50.00 M,
and the percentage change from the previous year is not available.
In 2023, Contineum Therapeutics, Inc. Class A Common Stock's net income was $22.72 M.
See Contineum Therapeutics, Inc. Class A Common Stock’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$50.00 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$195,000.00 |
$329,000.00 |
$0.00 |
| Gross Profit |
$49.81 M |
-$329,000.00 |
$0.00 |
| Gross Profit Ratio |
1 |
0 |
0 |
| Research and Development
Expenses |
$27.60 M
|
$16.89 M
|
$22.36 M
|
| General & Administrative
Expenses |
$6.32 M
|
$5.83 M
|
$6.29 M
|
| Selling & Marketing
Expenses |
-$195,000.00
|
-$329,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.13 M
|
$5.50 M
|
$6.29 M
|
| Other Expenses |
$0.00 |
-$92,000.00 |
-$91,000.00 |
| Operating Expenses |
$33.73 M |
$22.39 M |
$28.65 M |
| Cost And Expenses |
$33.92 M |
$22.72 M |
$28.65 M |
| Interest Income |
$4.61 M |
$761,000.00 |
$77,000.00 |
| Interest Expense |
$208,000.00 |
$388,000.00 |
$332,000.00 |
| Depreciation &
Amortization |
$195,000.00
|
$329,000.00
|
$325,000.00
|
| EBITDA |
$23.57 M
|
-$23.54 M
|
-$28.34 M
|
| EBITDA Ratio |
0.47 |
0 |
0 |
| Operating Income Ratio
|
0.32
|
0
|
0
|
| Total Other
Income/Expenses Net |
$7.09 M
|
-$1.53 M
|
-$354,000.00
|
| Income Before Tax |
$23.17 M |
-$24.25 M |
-$29.00 M |
| Income Before Tax Ratio
|
0.46
|
0
|
0
|
| Income Tax Expense |
$450,000.00 |
$0.00 |
$241,000.00 |
| Net Income |
$22.72 M |
-$24.25 M |
-$29.00 M |
| Net Income Ratio |
0.45 |
0 |
0 |
| EPS |
1.36 |
-0.97 |
-1.74 |
| EPS Diluted |
1.28 |
-0.97 |
-1.63 |
| Weighted Average Shares
Out |
$16.67 M
|
$25.13 M
|
$16.67 M
|
| Weighted Average Shares
Out Diluted |
$17.76 M
|
$25.13 M
|
$17.76 M
|
| Link |
|
|
|
